It refers to a pharmacological component, including a compound, represented by the following formula, in which the safe and effective area under the concentration curve is taken orally (0.1-1.0 mg per day) in patients with chronic kidney disease. The plasma electrode (ABC) has a bioavailability of 50% or more, ranging from 188 to 3173 ng/ml. Current inventions are useful in the treatment of chronic kidney disease (ERC) as a counteraction to ore codeine receivers (ARMs).Se refiere a una composicion farmaceutica que comprende al Compuesto I representado por la siguiente formula, en donde si la composicion se administra via oral (a una dosis diaria de 0.1 a 1.0 mg) a un paciente con enfermedad renal cronica, el area segura y eficaz bajo la curva de concentracion-tiempo del plasma (ABC) varia entre 188 y 3173 ng h/mL, y su biodisponibilidad es de 50 % o mas. La presente invencion es util como antagonista de receptor mineralocorticoide (ARM) para el tratamiento de la enfermedad renal cronica (ERC).
